FDA warns foreign drugmakers over mold, filthy facilities, and other GMP issues
Regulatory NewsEmily Hayes
Audit/inspectionComplianceGMPOTCPharmaceuticalsUnited StatesWarning lettersRegulatory NewsEmily HayesAudit/inspectionComplianceGMPOTCPharmaceuticalsUnited StatesWarning letters